Research Analysts Issue Forecasts for REVB FY2028 Earnings

Revelation Biosciences, Inc. (NASDAQ:REVB) – Analysts at Roth Capital decreased their FY2028 earnings estimates for Revelation Biosciences in a research note issued on Wednesday, December 4th. Roth Capital analyst J. Aschoff now anticipates that the company will post earnings per share of $2.03 for the year, down from their prior forecast of $2.06. The consensus estimate for Revelation Biosciences’ current full-year earnings is ($7.80) per share.

Revelation Biosciences Price Performance

Revelation Biosciences stock opened at $0.44 on Friday. The company’s 50-day moving average is $0.80 and its 200-day moving average is $1.27. The firm has a market capitalization of $1.89 million, a PE ratio of -0.03 and a beta of 0.15. Revelation Biosciences has a fifty-two week low of $0.42 and a fifty-two week high of $25.26.

Revelation Biosciences Company Profile

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.